Empery Asset Management Acquires 6.6M X4 Pharmaceuticals Shares, Boosting Portfolio
ByAinvest
Friday, Jan 23, 2026 5:34 am ET1min read
XFOR--
Empery Asset Management has acquired 6,545,732 shares of X4 Pharmaceuticals at $4 per share, marking a significant addition to its portfolio. The firm primarily invests in the healthcare and consumer cyclical sectors, reflecting its strategic focus on industries with significant growth potential. X4 Pharmaceuticals is a biopharmaceutical company developing novel therapeutics for rare immune system diseases. The acquisition positions X4 Pharmaceuticals as a significant component of Empery Asset Management's portfolio, accounting for 9.99% of its total holdings.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet